Literature DB >> 19857570

Oxidants induce alternative splicing of alpha-synuclein: Implications for Parkinson's disease.

Shasi V Kalivendi1, Deepthi Yedlapudi, Cecilia J Hillard, B Kalyanaraman.   

Abstract

alpha-Synuclein (alpha-syn) is a presynaptic protein that is widely implicated in the pathophysiology of Parkinson's disease (PD). Emerging evidence indicates a strong correlation between alpha-syn aggregation and proteasomal dysfunction as one of the major pathways responsible for destruction of the dopamine neurons. Using parkinsonism mimetics (MPP(+), rotenone) and related oxidants, we have identified an oxidant-induced alternative splicing of alpha-syn mRNA, generating a shorter isoform of alpha-syn with deleted exon-5 (112-syn). This spliced isoform has an altered localization and profoundly inhibits proteasomal function. The generation of 112-syn was suppressed by constitutively active MEK-1 and enhanced by inhibition of the Erk-MAP kinase pathway. Overexpression of 112-syn exacerbated cell death in a human dopaminergic cell line compared to full-length protein. Expression of 112-syn and proteasomal dysfunction were also evident in the substantia nigra and to a lesser extent in striatum, but not in the cortex of MPTP-treated mice. We conclude that oxidant-induced alternative splicing of alpha-syn plays a crucial role in the mechanism of dopamine neuron cell death and thus contributes to PD. Copyright 2009. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857570      PMCID: PMC4485429          DOI: 10.1016/j.freeradbiomed.2009.10.045

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  40 in total

1.  Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

Authors:  F J Lee; F Liu; Z B Pristupa; H B Niznik
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

Review 2.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association?

Authors:  Harry Ischiropoulos; Joseph S Beckman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  Development and survival of rat embryonic mesencephalic dopaminergic neurones in serum-free, antioxidant-rich primary cultures.

Authors:  N S Cheung; Y M Hickling; P M Beart
Journal:  Neurosci Lett       Date:  1997-09-12       Impact factor: 3.046

4.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

Authors:  Wolfgang Hoyer; Dmitry Cherny; Vinod Subramaniam; Thomas M Jovin
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

5.  Chaperone-like activity of synucleins.

Authors:  J M Souza; B I Giasson; V M Lee; H Ischiropoulos
Journal:  FEBS Lett       Date:  2000-05-26       Impact factor: 4.124

6.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

7.  Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.

Authors:  Günter U Höglinger; Géraldine Carrard; Patrick P Michel; Fadia Medja; Anne Lombès; Merle Ruberg; Bertrand Friguet; Etienne C Hirsch
Journal:  J Neurochem       Date:  2003-09       Impact factor: 5.372

8.  Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway.

Authors:  Srigiridhar Kotamraju; Yoshiko Tampo; Agnes Keszler; Christopher R Chitambar; Joy Joseph; Arthur L Haas; B Kalyanaraman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-04       Impact factor: 11.205

9.  NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.

Authors:  M Yoshimoto; A Iwai; D Kang; D A Otero; Y Xia; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

10.  Structural determinants of PLD2 inhibition by alpha-synuclein.

Authors:  Jacqueline E Payton; Richard J Perrin; Wendy S Woods; Julia M George
Journal:  J Mol Biol       Date:  2004-04-02       Impact factor: 5.469

View more
  20 in total

Review 1.  Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.

Authors:  Subhrangshu Guhathakurta; Eugene Bok; Baggio A Evangelista; Yoon-Seong Kim
Journal:  Prog Neurobiol       Date:  2017-04-23       Impact factor: 11.685

Review 2.  Agrochemicals, α-synuclein, and Parkinson's disease.

Authors:  Blanca A Silva; Leonid Breydo; Anthony L Fink; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-08-30       Impact factor: 5.590

Review 3.  Alternative splicing isoforms in health and disease.

Authors:  Hyoung Kyu Kim; Michael Huy Cuong Pham; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Pflugers Arch       Date:  2018-03-13       Impact factor: 3.657

4.  Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression.

Authors:  Jesse R McLean; Penelope J Hallett; Oliver Cooper; Michael Stanley; Ole Isacson
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

5.  Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6.

Authors:  Chantelle M Rein-Smith; Nathan W Anderson; David H Farrell
Journal:  Thromb Res       Date:  2012-10-01       Impact factor: 3.944

6.  JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.

Authors:  Won-Seok Choi; Hyung-Wook Kim; Zhengui Xia
Journal:  Toxicology       Date:  2014-12-09       Impact factor: 4.221

Review 7.  Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.

Authors:  Adrien W Schmid; Bruno Fauvet; Marc Moniatte; Hilal A Lashuel
Journal:  Mol Cell Proteomics       Date:  2013-08-21       Impact factor: 5.911

Review 8.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

9.  Splice isoform and pharmacological studies reveal that sterol depletion relocalizes α-synuclein and enhances its toxicity.

Authors:  Julie S Valastyan; Daniel J Termine; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 10.  Up-regulation of SNCA gene expression: implications to synucleinopathies.

Authors:  L Tagliafierro; O Chiba-Falek
Journal:  Neurogenetics       Date:  2016-03-07       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.